CDH Leads USD108m Series C for China’s IASO

CDH Baifu, an asset management platform under CDH Investments, led a USD108m Series C for IASO Biotherapeutics, a China-based clinical-stage biopharmaceutical company, with participation from CCB International, Everbright, Co-Stone Capital, CNCB Capital and Plaisance Capital, and follow-on from GL Ventures. Read more… Read More



(default archive template)